Freddy Mendez Torres, MD
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $81,677 of the $95,316 with a category attached, or 85.7%. Johnson & Johnson accounts for 81.0% of it on its own, with 23 other manufacturers making up the rest. Among urology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $577.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$77K
- Medtronic$14K
- Procept Biorobotics Corporation$1K
- Teleflex LLC$360
- Boston Scientific$269
- Verity Pharmaceuticals Inc.$228
- plus $2K from 18 others
What the payments were for
- Consulting fees$6,2407%
- Speaking & faculty fees$81,67786%
- Travel & lodging$2,3262%
- Food & beverage$4,8015%
- Education$2730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 77 | $77,241 |
| Medtronic(2 entities) | 24 | $14,484 |
| Procept Biorobotics Corporation | 6 | $1,189 |
| Teleflex LLC | 4 | $360 |
| Boston Scientific | 8 | $269 |
| Verity Pharmaceuticals Inc. | 2 | $228 |
| Johnson And Johnson International | 10 | $198 |
| AbbVie(2 entities) | 8 | $159 |
| Pfizer | 3 | $157 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Progenics Pharmaceuticals, Inc. | 1 | $124 |
| Travere Therapeutics, Inc. | 2 | $118 |
| Ferring Pharmaceuticals Inc. | 3 | $113 |
| Olympus Latin America, Inc. | 1 | $81 |
| Merck | 3 | $75 |
| Stryker | 1 | $74 |
| Seagen Inc. | 1 | $55 |
| Profound Medical Corp. | 1 | $54 |
| Covidien LP | 1 | $48 |
| Bayer Puerto Rico Inc. | 2 | $47 |
| Tolmar, Inc. | 2 | $42 |
| PBG Puerto Rico LLC | 2 | $40 |
| Tolmar Pharmaceuticals, Inc. | 1 | $19 |
| BD | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$75,399
- DARZALEX$35,733
- TALVEY$27,483
- RYBREVANT$24,735
- INTERSTIM$13,827
- AquaBeam Robotic System$1,119
- AKEEGA$1,100
- UroLift System$328
- CARVYKTI$278
- TRELSTAR$203
- OPDIVO$125
- PYLARIFY$124
- rezum Generator$100
How this compares
$95,316 in reported general payments places this provider in the 95th percentile of 122 urology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 182 | $2,707,572 |
| XtandiEnzalutamide | 40 | $567,056 |
| Lupron DepotLeuprolide Acetate | 22 | $224,245 |
| EligardLeuprolide Acetate | 66 | $152,642 |
| ElmironPentosan Polysulfate Sodium | 148 | $100,906 |
| OrgovyxRelugolix | 23 | $61,434 |
| TrelstarTriptorelin Pamoate | 11 | $56,583 |
| MyrbetriqMirabegron | 100 | $46,572 |
| Tolterodine Tartrate ErTolterodine Tartrate | 789 | $34,284 |
| Tamsulosin Hcl | 3,343 | $31,197 |
| FirmagonDegarelix Acetate | 43 | $21,291 |
| Bethanechol Chloride | 332 | $15,619 |
| Oxybutynin Chloride ErOxybutynin Chloride | 1,112 | $15,413 |
| Bicalutamide | 456 | $13,346 |
| Finasteride | 1,199 | $11,411 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $77,241 | $2,707,572182 claims |
| AbbVieLupron Depot, Synthroid | $159 | $225,38545 claims |
| Tolmar Pharmaceuticals, Inc.Eligard | $19 | $152,64266 claims |
| Verity Pharmaceuticals Inc.Trelstar | $228 | $56,58311 claims |
| Ferring Pharmaceuticals Inc.Firmagon | $113 | $21,29143 claims |
| PfizerToviaz | $157 | $5,28716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 122 urology providers in Puerto Rico.
Other urology in Cayey
- Claudio Bernaschina BobadillaPonce$132K
- Mariela Martinez-RiveraPonce$105K
- Luis AmbertRio Piedras$64K
- Jorge Crespo CarrilloRio Piedras$62K
- Ronald Cadillo ChavezBayamon$61K
- Andres Perez RomanSan Juan$58K
- Rafael Bouet BlasiniSan Juan$55K
- Antonio Yulian ValentinCaguas$48K
- Alberto Ramirez LopezDorado$47K
- Jose Saavedra-BelaundeSan Juan$45K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.